Singapore-based biopharma firm ASLAN Pharmaceuticals has filed for a proposed initial public offering (IPO) in the US to raise capital for clinical development of its products and trials.
The Taipei Exchange-listed company on Monday filed a registration statement with the Securities and Exchange Commission (SEC) for the proposed issue of its American Depository Shares (ADSs) on Nasdaq. In a statement, it said the number of ADSs to be offered, and the price range for the proposed offering are yet to be determined.
